Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian concern at GMO trial approval delays

A consortium of Indian agricultural biotechnology companies has urged the country’s Environment Minister to convene a special meeting of the Genetic Engineering Appraisal Committee (GEAC), reports Indian newspaper The Times of India. The consortium of 14 leading companies, Able-Ag, made the appeal as the GEAC had cancelled its June meeting. No meeting was held in April and the field trial agenda was not discussed at the meeting in May. That is having an impact on field trials to be held in the kharif (summer) season. Able-Ag has expressed concern over mounting applications for field trial approvals since April and stressed that timely approvals are necessary to generate reliable data about efficacy, safety and agronomic performance of the products without losing one year. A separate letter has also been sent to the Agriculture Minister. The next meeting of the GEAC is scheduled to be held in July.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG004789

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel